Oxford Covid biotech firm makes stellar debut on London stock market

Shares of Oxford Nanopore close up 44%, giving co-founder paper fortune of £63mSee all our coronavirus coverageOxford Nanopore, whose DNA sequencing technology has been essential in tracking Covid-19 variants globally, has made a stellar stock market debut in London. A rise in its share price of as much as 47% has left the firm valued at almost £5bn.The flotation of the Oxford University spin-out has given its chief executive and co-founder, Gordon Sanghera, a fortune on paper of £63m.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: IPOs FTSE Stock markets Nanotechnology Biochemistry and molecular biology Science University of Oxford Business UK news Source Type: news